Fu Cai-Yun, Kong Zi-Qing, Long Yuan, Chen Qiang, Wang Rui
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, and Institute of Biochemistry and Molecular Biology, Lanzhou University, 222 Tian Shui South Road, Lanzhou 730000, People's Republic of China.
Eur J Pharmacol. 2007 Oct 31;572(2-3):175-81. doi: 10.1016/j.ejphar.2007.06.014. Epub 2007 Jun 21.
Rat/mouse hemokinin-1 is a mammalian tachykinin peptide whose biological functions have not been well characterized. In the present study, an attempt has been made to investigate the effect and mechanism of action of rat/mouse hemokinin-1 on systemic arterial pressure after intravenous (i.v.) injections in anesthetized rats by comparing it with that of substance P. Our data showed that injection of rat/mouse hemokinin-1 (0.1, 0.3, 1, 3 and 10 nmol/kg) lowered systemic arterial pressure dose-dependently. This effect was significantly blocked by pretreatment with SR140333 (a selective tachykinin NK1 receptor antagonist) and the NO synthase inhibitor L-NAME (Nomega-nitro-L-arginine methyl ester hydrochloride), respectively, but was not affected by bilateral vagotomy or the muscarinic receptor blocker atropine. Compared to rat/mouse hemokinin-1, a dose of 3 nmol/kg of substance P caused biphasic changes in systemic arterial pressure (depressor and pressor responses). The results suggest that the mechanism of the depressor response caused by substance P was similar to rat/mouse hemokinin-1 in that it was inhibited by SR140333 and L-NAME, respectively, but that there was a component of the cardiovascular change induced by rat/mouse hemokinin-1 (but not substance P) that was attenuated by SR48968 (a selective tachykinin NK2 receptor antagonist). The depressor response induced by rat/mouse hemokinin-1 (i.v.) might be explained primarily by the action on endothelial tachykinin NK1 receptors to release endothelium-derived relaxing factor (NO) and this effect was not affected by vagal components. In addition, rat/mouse hemokinin-1 could not induce the pressor response through stimulation of sympathetic ganglion like substance P in anesthetized rats.
大鼠/小鼠血红蛋白-1是一种哺乳动物速激肽肽,其生物学功能尚未得到充分表征。在本研究中,通过将大鼠/小鼠血红蛋白-1与P物质进行比较,试图研究其静脉注射(i.v.)后对麻醉大鼠全身动脉压的作用及其作用机制。我们的数据表明,注射大鼠/小鼠血红蛋白-1(0.1、0.3、1、3和10 nmol/kg)可使全身动脉压呈剂量依赖性降低。这种作用分别被SR140333(一种选择性速激肽NK1受体拮抗剂)和NO合酶抑制剂L-NAME(Nω-硝基-L-精氨酸甲酯盐酸盐)预处理显著阻断,但不受双侧迷走神经切断术或毒蕈碱受体阻滞剂阿托品的影响。与大鼠/小鼠血红蛋白-1相比,3 nmol/kg的P物质剂量可引起全身动脉压的双相变化(降压和升压反应)。结果表明,P物质引起的降压反应机制与大鼠/小鼠血红蛋白-1相似,即分别被SR140333和L-NAME抑制,但大鼠/小鼠血红蛋白-1(而非P物质)诱导的心血管变化中有一部分被SR48968(一种选择性速激肽NK2受体拮抗剂)减弱。大鼠/小鼠血红蛋白-1(i.v.)诱导的降压反应可能主要是由于作用于内皮速激肽NK1受体以释放内皮源性舒张因子(NO),且这种作用不受迷走神经成分的影响。此外,在麻醉大鼠中,大鼠/小鼠血红蛋白-1不能像P物质那样通过刺激交感神经节诱导升压反应。